Presented by
Falconbury
Drafting Commercial Contracts for the Pharmaceutical Industry Training Course
A two-day practical and interactive seminar focusing on current contract drafting, negotiating, best practice and related issues within the pharmaceutical, biotech and life sciences sectors.
★★★★★ "Definitely worth the price!"
20-21 November 2024 »
from £1199.00
- Format: Live online
- CPD: 12 hours for your records
- Certificate of completion
Course overview
In such a highly regulated industry and in these turbulent and uncertain times, understanding the key challenges of negotiating and drafting an effective and watertight contract on an international level are complex topics. They can be difficult for even the most well-equipped in-house lawyer and most often it is not the lawyer in the driving seat.
Commercial managers from all areas of the pharmaceutical industry are leading negotiations and drafting and managing key contracts on a daily basis. It is vital that both legal counsel and commercial executives not only have the key skills and tactics to create a win:win scenario but also the knowledge to ensure any agreement is within current laws and regulations. The alternative is the exposure of the organisation to unnecessary risk and costly disputes.
This programme will:
- Deliver an in-depth examination of intellectual property issues that affect pharmaceutical industry agreements
- Focus on competition regulations pertinent to pharmaceutical industry agreements
- Analyse the commercial and legal issues affecting pharmaceutical industry agreements
- Examine collaboration and licensing agreements
This unique and highly interactive two-day programme looks at all stages of the contracting process and aims to deliver applied training through a balanced blend of practical learning. The presenters will use a mixture of practical exercises and cases from the pharmaceutical industry to ensure you leave the seminar with the knowledge and skills to perfect all stages of the contracting process.
This training course is part of our Commercial Contracts Training Course collection which has been designed for the in-house lawyer.
Who should attend?
Personnel from R&D, clinical, regulatory, commercial, sales and marketing, manufacturing, distribution and purchasing functions, including:
- In-house counsel
- Commercial and contract managers
- Business development managers
- Purchasing and procurement personnel
- Heads of legal departments
- Legal advisers
- Patent, IP, trade marks or licensing counsel
Benefits of attending
By attending this seminar, you will:
- Update your practical skills when drafting effective licensing and collaboration agreements
- Explore the current issues relating to IP including the Unitary Patent and Unified Patent Court
- Understand the key intellectual property issues affecting pharmaceutical industry agreements
- Explore the implications of SPCs for pharmaceutical industry agreements
- Learn how to draft contracts to avoid anti-trust infringement
- Familiarise yourself with the key commercial and legal issues that affect pharmaceutical industry agreements
- Gain knowledge of the key issues in clinical trial agreements, contract manufacturing agreements and co-promotion, co-marketing and distribution agreements, and material transfer agreements
- Get to grips with competition law relevant to doing deals in the pharmaceutical industry and best practice tactics to use
This course will cover:
Understanding licensing and collaboration agreements
- Precontractual documents and the role of the term sheet
- Scope of the licence
- The interplay of key commercial terms, including:
- governance and dispute resolution
- performance obligations and termination rights
- financial terms
- Boilerplate clauses, including law and jurisdiction
Workshop: Understanding licensing and collaboration agreements
The Unitary Patent and the UPC One Year On
- Latest developments
- Implications for the pharmaceutical industry
Third-party IP rights – freedom-to-operate searches and implications for pharmaceutical industry agreements
- Evaluating your freedom to operate
- Different approaches to infringement in Europe
- Assessment of injunction risk
- Mitigating risk and pre-launch patent strategies more generally
- Strategies for obtaining freedom to operate including via licensing
- Freedom-to-operate warranties and indemnities
- Payments and royalty stacking
- Enforcement against infringers
- No-challenge clauses
- Benefits of recording your licence
Supplementary protection certificates (SPCs) – securing the full commercial potential of your product
- What are SPCs?
- What are the implications for pharmaceutical industry agreements?
- The duration of the SPC
- What does the SPC cover?
- Combination products
- Basic patents and basic follow-on SPCs
- Leveraging the full commercial value of your property
Understanding and drafting R&D agreements
- The scope and purpose of R&D agreements
- Key terms and conditions
- Limitations of experimental use defence to patent infringement
- The 'Euro Bolar' defence: Article 10(6) Directive 2001/83/EC explained
- The varying scope of the 'Euro Bolar' defence across the EU and how it has been implemented in UK law
Medicines regulations using regulatory processes to define contractual obligations
- An introduction to regulatory law
- Brief contrast of differing regulatory regimes: medicines/ devices
- Milestones in approving medicines
- Using regulatory processes and milestones in defining contractual obligations
- Common pitfalls and hot spots
Key issues in clinical trials and related agreements
- Introduction to clinical trials
- Outline of principal EU and UK legislation
- Horizon scanning: preparing for regulatory change
- Structuring clinical trial agreements
- Engaging CROs
- Key agreement terms and obligations
- Liability, indemnities and insurance
Key issues in contract manufacturing agreements
- The importance of the GMP audit
- Issues with technology transfer
- Apportionment of risk and reward
- Secondary sources of supply
- Building a supply chain
- Other key issues
Key issues in co-promotion, co-marketing and distribution agreements
- Introduction to the agreements
- Scoping the deal
- Preparing for contingencies and termination
- Key characteristics of the distribution relationship
- Key terms – scope of rights and responsibilities, restrictions, minimum purchase requirements, territory
Key issues in material transfer agreements
- The purpose of the agreement
- The scope of the agreement
- Key terms and conditions
- Key issues to be aware of
Introduction to relevant EU competition law rules
- Article 101 TFEU and 102 TFEU: restrictive agreements and practices and abuse of dominance in pharmaceutical markets
- The December 2010 Horizontal Cooperation Guidelines
- The Jan 2011 R&D Block Exemption – strategy for early joint research
- The Technology Transfer Block Exemption – dos and don’ts for licensing in and out
- The Vertical Agreements Block Exemption and Vertical Restraints Guidelines – designing distribution models in the EU
- Specialisation Agreements Block Exemption
- Implications of Brexit
Practical workshop: Current competition law issues
- Reduced and exclusive distribution agreements
- Licensing in and out
- The new technology transfer exemption
- Quota schemes and other devices for protecting domestic needs
- Discount schemes for dominant companies
Mario Subramaniam
Bird & Bird
Mario is a partner at Bird & Bird and an IP and transactions specialist with extensive experience in the Life Sciences. He advises global Life Science clients on strategic IP licensing, collaboration and partnering transactions. He also supports those clients with M&A, joint ventures, asset acquisitions and disposals, strategic manufacturing, supply and outsourcing arrangements. Prior to qualifying as a solicitor, Mario worked as a research scientist in the fields of tumour immunology and molecular biology. Having spent a significant period of his career in-house advising Life Science clients, Mario brings a wealth of experience and a unique perspective to clients contemplating strategic transactions and partnerships. His experience and approach also brings great synergy to Bird & Bird's outstanding Life Sciences offerings, allowing an unrivalled opportunity to support clients with their most pressing challenges.
Ben Thomas
Simmons & Simmons LLP
Ben Thomas is a Managing Associate at Simmons & Simmons. He has experience of working across a range of contentious and non-contentious intellectual property matters, with a focus on patent and supplementary protection certificate litigation. Assisted by his strong technical background in biochemistry, Ben has a particular interest in the life sciences sector. He has acted for clients in a wide variety of industries, including pharmaceuticals, vaccines and medical devices, TMT and consumer goods (e.g. laundry detergents, vaping devices). He has acted for clients in disputes before the English Patents Court, the UK and European Union Intellectual Property Offices, and the General Court and Court of Justice of the European Union.
James Agnew
Simmons & Simmons LLP
James Agnew is a supervising associate at Simmons & Simmons. He has worked on a range of contentious and non-contentious intellectual property matters including commercial licensing, collaboration agreements, software protection, settlement proceedings and the intellectual property aspects of corporate transactions, financings and commercial arrangements. James also advises on life sciences regulatory issues including the promotion of medicines and devices and interactions with healthcare professionals. He has experience in a wide range of industries, including life sciences, TMT, finance, Fintech, energy and defence, with a focus on transactions involving intellectual property.
Fred Nicolle
Simmons & Simmons
Fred Nicolle is a UK and European qualified patent attorney (CPA, EPA) at Simmons & Simmons. He has over 15 years experience specialising in patent prosecution and contentious matters for the life sciences sector. He has particular expertise in pharmaceuticals, medical devices, consumer health products, cosmetics, foods and health supplements. He graduated from the University of Cambridge with a Master of Natural Sciences degree with a final year research project in synthetic organic chemistry.
Fred has extensive experience of contentious patent proceedings in opposition at the European Patent Office and in national litigation, having defended patents for numerous commercially important products. Notable examples include the defence of patents for Noctiva™ (desmopressin acetate nasal spray), Bendeka® (bendamustine HCl injection), Revlimid® (lenalidomide), Xeplion®/Invega Sustenna® (paliperidone palmitate), wound dressings, and contact lenses.
Fred is featured in The Legal 500 and IAM Patent 1000 as a recommended patent attorney.
Ewan Townsend
Arnold & Porter
Ewan Townsend is Counsel in Arnold & Porter’s London office and assists clients in the life sciences sector on regulatory and commercial matters. He has experience with a broad range of regulatory issues that arise throughout the medicinal product and medical device life cycle, including research and development, clinical trials, marketing authorisations, manufacturing, distribution, advertising, pricing and reimbursement. Ewan’s work also includes drafting and negotiating commercial agreements for his life sciences clients, such as licence agreements, manufacturing, distribution and supply agreements, clinical trial agreements and service agreements, and advising on the intellectual property and regulatory issues that arise in the context of those transactions.
Stephen Reese
Clifford Chance LLP
Stephen Reese is a partner at Clifford Chance and advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. Stephen represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights. With significant experience representing clients within the life sciences and technology fields, Stephen has acted on some of the most significant licensing transactions in the life sciences industry. Since 2010, Stephen has been listed as one of IAM’s Top 250 Patent Licensing specialists.
Niels Ersbøll
Arnold & Porter LLP
Niels Ersbøll, Partner, Arnold & Porter LLP, advises clients on EU competition law in relation to cartels and restrictive practices, merger control, abuse of dominance and State aid. He is currently involved in several pending EU cartel investigations. He advises on merger control investigations by the European Commission and competition authorities worldwide for clients such as General Electric, Boston Scientific, Pfizer, and Sanyo. Where investigations (mergers or cartels) are run by several authorities in parallel, he assists with overall strategy and coordination. Niels also has significant experience helping clients with designing and implementing compliance measures and conducting internal investigations and audits.
Peter Rudd-Clarke
Osborne Clarke
Peter specialises in helping businesses navigate regulatory challenges and liability risks, particularly in the life sciences, healthcare and consumer products sectors.
Peter advises a range of businesses including medical device companies, software producers, pharmaceutical manufacturers, service providers and producers of lifestyle products.
His regulatory experience includes advising on the regulation of medical devices and consumer products, as well as CE/UKCA marking, clinical trials, regulatory investigations, the application of industry codes and ongoing compliance matters.
The litigation and risk management side to Peter’s practice involves defending manufacturers of complex products against liability claims, often across multiple jurisdictions; as well as advising clients on product recalls and corrective actions.
Peter is ranked in the Legal 500.
Sharmela Kalmer
Gowling WLG
Sharmela Kalmer is a Partner at Gowling WLG (UK) LLP. Sharmela is a trusted advisor to a number of emerging and established innovative technology and life sciences companies operating in a range of sectors, including biotech and medtech. With a wealth of industry experience, Sharmela's sector knowledge gives her a solid understanding of the opportunities and issues faced by clients and how to navigate these issues to access new market opportunities.
Clive Thorne
McCarthy Denning
Clive’s practice encompasses all areas of intellectual property; including patents, copyright, trademarks, passing off, breaches of confidence, privacy and data law. He has wide international experience, particularly in the Far East, and is admitted to practice in Hong Kong and Australia. He has handled disputes in all relevant courts including the High Court, IPEC, Court of Appeal, Privy Council and UK Supreme Court. Clive is a firm believer in the value of arbitration for determining IP disputes and has been appointed to sit as an arbitrator by inter alia, ICC, WIPO and in specialist panels. He has written and lectured widely on IP law and recently published the latest edition of “Users Guide to Copyright.”
Clive trained at Clifford-Turner and later practised in the UK and Hong Kong with Baker-Mckenzie. For many years he headed the IP practice at Denton Hall and subsequently at Arnold and Porter. More recently he was a partner at RPC and Wedlake Bell and Special Counsel at Baker -Botts.
He has acted for clients in many industrial fields including; IT, aerospace, retail, pharmaceutical and healthcare, toys and games, publishing, food, press, advertising and air-conditioning. He has also handled many leading IP actions.
Recent work has included acting for the successful party in the Court of Appeal in a patent action relating to wound dressing technology, handling a multi-jurisdictional copyright and trade mark dispute for a Hong Kong food manufacturer, acting for an intervening party in the UK Supreme Court in the constitutionally important Article 50 judicial review, handling a design protection campaign for a New Zealand manufacturer of distinctive kitchenware and defending patent attorneys in professional negligence claims.
NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:
- 30% off the 2nd delegate*
- 40% off the 3rd delegate*
- 50% off the 4th delegate*
Please contact us for pricing if you are interested in booking 5 or more delegates
20-21 November 2024
Live online
09:30-17:00 UK (London) (UTC+00)
10:30-18:00 Paris (UTC+01)
04:30-12:00 New York (UTC-05)
Course code 14039
- GBP 1,199
- EUR 1,719
- USD 1,959
Limited places remaining
- 2 days live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.
Reviews of IPI's Drafting Commercial Contracts for the Pharmaceutical Industry training course
Definitely worth the price!
Jul 8 2024
Roberta Comerro 
Legal Counsel & COmpliance Officer, Linnea
Jul 8 2024
I enjoyed the credibility behind each speaker. I enjoyed that they had practiced within the industry and were able to respond well to questions/ generate discussion.
Rachael McConnell 
Director of Operations, Catalent
Jul 10 2023
All presentations were nicely structured and have provided clear and understandable insights into individual issues in the pharmaceutical industry. Very pleasant environment and very high quality speakers.
Patricia Baratova 
Legal Counsel , Sun Pharmaceutical Industries (Europe) B.V.
Nov 23 2022
Excellent webinar, I would (and did) highly recommend it. Large variety of subjects with much useful insights and information. The different speakers make it more dynamic and they were all very open to discussion and/or taking questions.
Juliette Gordeau
Legal Counsel, TRB Chemedica International S.A.
Nov 24 2021
I found the webinar very informative and helpful. The speakers were very clear and practice-oriented.
Maria João Rodrigues 
Legal Counsel, BIAL - Portela & Companhia SA
Nov 24 2021
Overall it was very good
Cristina Bertulli
Director of Business Development and Operations , Exactmer Ltd
Nov 19 2019
This course was brilliant and covered all the key points. The speakers were highly knowledgeable and had practical insights and fresh perspectives on drafting issues and implications. Having multiple speakers allowed for a fresh and dynamic course, and increased the amount of information absorbed.
James Langston
Contracts Manager, AstraZeneca
Nov 19 2019
Good overview of content, great organisation.
Amish Unka
Legal Counsel, Morningside Healthcare Limited
Jun 5 2019
High quality content and course materials. Professional presentation within a relaxed learning environment. Fantastic speakers who were happy to answer questions during their talks and the breaks.
Grace Hamlett
Legal Counsel, Mereo BioPharma
Nov 20 2018
Insightful teachers, great take-home material, stupendous learning environment.
Luis Briseno Roa 
Associate Director, Alexion R&D France
Nov 20 2018
A fantastic program and great speakers/participants.
Mia Rensch-Jacobsen 
Business Operations Manager, Roche Innovation Center Copenhagen
Jun 6 2018
All speakers are excellent and experts in their fields – I really enjoyed listening to them. The course is very extensive covering a wide variety of topics.
Avadhanula Yagna Praveen Kumar 
Head of Intellectual Property Management, Pharmaniaga Berhad
Nov 20 2018
Very useful course for my future career.
Christopher France 
Business Development Associate, GSK Vaccines Srl
Nov 20 2018
Great and useful course.
Taisier Adil
Legal Counsel, Xendo Holding B.V. – A ProPharma Group Company
Jun 6 2018
Good topics and speakers.
Wan Intan Idura Wan Ismail
Deputy Director, PHARMANIAGA BERHAD
Jun 6 2018
Excellent and immediately useful.
Dan Hudson
Manager, GSK Vaccines SRL
Jun 6 2018
I particularly liked the quality of the speakers and the various workshops.
Zian Bertrand
In-House Counsel , ERYTECH PHARMA
Nov 20 2017
I think that overall the course material was comprehensive and touched on a lot of different topics. I would recommend this course.
Angele Azzopardi 
In House Legal Counsel , Starpharma Malta
Nov 20 2017
Very good course and good presentations/topics.
Ilaria Pastorello 
Manager Vaccines Business Development, GSK Biologicals SA
Nov 20 2017
The content was very good and I appreciated the booklet provided. I found ... the speakers very engaging and everything was well organised and well presented.
Leah Baker
Pharmacovigilance Scientist, Norgine Ltd
Nov 20 2017
I found the course very practical and engaging
Tania Damianova
Company Lawyer, UCB S.A.
Jun 7 2017
The content is excellent. The speakers are highly qualified and talented in terms of lecturing.
Moataz Mahmoud 
Legal & Compliance Advisor, EBN Sina Medical Establishment
Nov 20 2017
Very informative, very knowledgeable speakers, content good.
Luciana Schwambach
Contract Manufacturing Business Development Director, Xellia Pharmaceuticals ApS
Nov 20 2017
Very knowledgeable experts.
Olivia Chalwin
Major Contracts Manager, University of Southampton
Jun 7 2017
Very good, good alignment with professional practice.
Erik Popping
Corporate & Legal Counsel, Intravacc
Nov 23 2016
Great material and speakers
Paraskevi Sakallaridi 
Lawyer, ELPEN Pharmaceutical Co. Inc.
Nov 23 2016
Good overall impression. Certain topics remained at introductory level without going into depth
Lina Yaneva
Legal Counsel, Mylan SAS
Jun 8 2016
The course was well organised. Unfortunately patent issues were skimmed over
Jeremy Whitman
Legal Department, Sterling S.p.A.
Nov 23 2016
Very interesting topics
Khady Seck
Mylan S.A.S.
Nov 18 2015
Very well organised, really enjoyed the higher energy speakers as I find it difficult to sit through three days if the speakers are low energy
Darragh O'Dea 
Legal Counsel, BioMarin Pharmaceutical
Nov 18 2015
The course was good. I would suggest more practical examples.
Elda Selfo
Site Contract Specialist , INC Research
Nov 18 2015
Overall good. The seminar room with no windows and fresh air was the only negative.
Kristina Anna Reitmeier 
European PharmInvent Services, s.r.o.
Jun 2 2015
Very professional. Some of the speaker were too fast, but all of them very friendly and kind.
Roberto Aldovini
Legal Counsel, APR Applied Pharma Research s.a
Jun 2 2015
Enough but not very deep
Eva Rosal Negre 
Legal Advisor , Laboratories Hipra, S.A
Jun 2 2015
Organisations are paying a considerable amount for their employees to attend this course and the speakers should therefore deliver better presentations. The good speakers were engaging, interested in feedback and seemed to care. Given the professional level of the speakers the lack of professionalism in the way that they presented their subject in the time available was surprising.
Rachel Simpson
Contracts Manager, University of Dundee
Nov 18 2015
Days 1-2 were very detailed, although some presenters did not encourage interaction
Neil Thompson
Supply Chain Manager, Suir Pharma Ireland
Nov 19 2014
Generally high quality speakers. Good all-round refresher and networking opportunity.
Nick Plummer
Senior Director, EU Legal Services , Patheon UK Ltd
Nov 19 2014
The content was really interesting and useful, was communicated effectively and all the presenters were good. The negotiation part was great!
Eleni Pentafragka
ELPEN S.A.
Nov 19 2014
Very helpful for practising in-house lawyers courses. The negotiation strategies workshop should have been adapted to lawyers.
Maria Ganeva
Contracts Manager, Genzyme
Nov 19 2014
Speakers were fine and knew the subject well but some presentations were superficial
Maria Teresa Vazquez Calo
Lawyer, Assesora estudio jurídico y tributario S.L.P
Nov 19 2014
More case studies would be better
Jan Smidrkal
Tech Transfer Manager, Institute of Chemical Technology Prague
Jun 3 2014
Very good course, but many details covered in a short time.
Christopher Lambert
Chief Legal Officer, Fertin Pharma A/S
Nov 18 2013
The course was excellent, very useful and well organized.
Borislav Dakic 
Director of Legal Department, Hemofarm AD
Nov 18 2013
Really excellent including Susan Sungleton
Patricia Hoyle
Global Head Intellectual Property, Evolva Holding SA
Jun 5 2013
Speakers were well prepared and had good presentation skills. I enjoyed the course.
Dragan Lutz 
SENIOR LICENSING MANAGER, JADRAN-GALENSKI LABORATORIJ d.d.
Nov 18 2013
Content was useful, but I would recommend a bit more focus on generics as well. All speakers were competent and presented well.
Milica Milekic
Senior Legal Counsel, HEMOFARM AD
Jun 5 2013
Lots of content, some very good presentations and speakers.
Rebecca Flory
Solicitor, Edinburgh Research & Innovation Ltd
Nov 12 2012
Very relevant and useful to the topic of drafting commercial agreements in the pharma industry
Asif Altaf
Allergan Ltd
Nov 12 2012
Very helpful and detailed material, good coverage of all pharma legal issues considering time available.
Roberta Comerro
Ginsana SA
Nov 12 2012
Given the various topics being covered in a span of 3 days I think the speaker couldn't have done better
Sangeeta Shah
Mercury Pharma
United Kingdom
- Torbay Pharmaceuticals
- 3M Health Care Ltd
- Accord Healthcare
- Adaptimmune Limited
- Adaptimmune Ltd
- Allergan Ltd
- Almac Group
- Almac Group Limited
- Anderson Law LLP
- Apotex
- Ark Therapeutics Ltd
- Arnold & Porter (UK) LLP
- Artios Pharma Limited
- Astellas
- Astellas Pharma Europe Ltd
- AstraZeneca
- AstraZeneca (Macclesfield)
- Autolus
- Bard Pharmaceuticals
- Biofocus DPI
- Boehringer
- Boehringer Ingelheim Limited
- Bristol-Myers Squibb Pharmaceuticals Limited
- Bristows LLP
- Britannia Pharmaceuticals Ltd
- British American Tobacco
- Burges Salmon
- Cancer Research UK
- Catalent
- Centroflora CMS
- Chemidex Pharma Limited
- Clearly Gottlieb Steen & Hamilton
- Clinuvel UK Ltd
- CMC Biopharmaceuticals
- Coalition for Epidemic Preparedness Innovations
- Consilient Health
- CONSORT MEDICAL PLC
- Corin Limited
- Covington & Burling
- Covington & Burling LLP
- Dechra Pharmaceuticals plc
- Dexcel Pharma Ltd
- Dickinson Dees LLP
- Dishman Europe Ltd
- Dr Reddys
- Edinburgh Research & Innovation
- Edinburgh Research & Innovation Ltd
- Emergent Product Development UK Ltd
- EUSA Pharma (UK) Ltd
- Evotec UK LTd
- Evox Therapeutics
- Exactmer Ltd
- F2G Ltd
- Ferring Pharmaceuticals Ltd
- GE Healthcare Limited
- Genzyme Therapeutics Ltd
- Gilead Sciences
- GlaxoSmithKline
- GlaxoSmithKline Services Unlimited
- Glenmark Pharmaceuticals Europe R&F Ltd
- GW Pharmaceuticals
- IDIS Ltd
- INC Research
- Indivior PharmaceuticalUK Ltd.
- Juniper Pharma Services Ltd
- Kent Pharmaceuticals Ltd
- Lonza Biologics
- Merck Sharp and Dohme Limited
- Mercury Pharma
- Mereo BioPharma
- Mitsubishi Tanabe Pharma Europe Ltd
- Morningside Healthcare Limited
- Muckle LLP
- Mundipharma International Limited
- Mylan
- Mylan Inc
- Napp
- Napp Pharmaceutical Holdings Ltd
- Napp Pharmaceuticals Ltd
- Nicoventures Limited
- Norbrook Laboratories
- Norgine Ltd
- Nottingham University Hospitals NHS Trust
- Nova Laboratories Ltd
- Novo Nordisk
- Otsuka Pharmaceutical Europe Ltd
- Oxagen Ltd
- Oxford Biomedica
- Oxford BioTherapeutics
- Patheon UK Ltd
- Penn Pharma
- Porton BioPharma
- Porton Biopharma Limited
- Porton Biopharma Ltd
- QA Ltd
- Randox Laboratories Limited
- Roche Products Ltd
- Rosemont Pharma Ltd
- Servier Labs Ltd
- Seven Seas Ltd
- Sigma Aldrich Co Ltd
- Sosei Heptares
- Synth-Isis Ltd
- Takeda
- Teva UK Ltd
- The University of Edinburgh
- Tillotts Pharma AG
- UBC late stage(UK)Ltd
- UCB Pharma
- University of Dundee
- University of Southampton
- Vectura Ltd
- Vertex Pharmaceuticals (Europe) Ltd
- Vitabiotics Ltd
- Volition Diagnostics UK Ltd
- VWV
- Warner Chilcott (UK) Ltd
- West Pharmaceuticals Services Ltd
Switzerland
- Acino International
- Acino International AG
- Actelion Pharmaceutical Ltd
- APR Applied Pharma Research s.a
- Bachem AG
- Biogen Idec
- BUHLMANN LABORATORIES AG
- CHEMO SA, Lugano Branch
- CimArk SA
- Clinuvel AG
- Debiopharm International SA
- DNDi
- Drugs for Neglected Diseases initiative (DNDi)
- Evolva Holding SA
- F Hoffmann La Roche AG
- F. Hoffmann-La Roche Ltd
- Factor
- Ferring International Center S.A.
- Ginsana SA
- Helsinn Chemicals SA
- Helsinn Healthcare S.A.
- Helsinn Healthcare SA
- Linnea
- Merck Serono SA
- MMV Medicines for Malaria Venture
- Novartis Consumer health
- Novartis Consumer Health S.A.
- Novartis Pharma AG
- Octapharma AG
- OM Pharma
- OM Pharma SA
- Siegfried AG
- Siegfried Ltd
- Stragen Pharma SA
- Takeda Pharmaceuticals International GmbH
- The Medicines Patent Pool Foundation
- TILLOTTS AG
- tillotts pharma AG
- TRB Chemedica International S.A.
- TRB Chemedica SA
- Vifor (International) Ltd.
- Vifor Pharma Ltd.
Germany
- 3M Deutschland GmbH
- BERLIN-CHEMIE AG
- Biontech AG
- BioNTech Business Services GmbH
- BioNTech SE
- Biotest AG
- Boehringer Ingelheim
- Boehringer Ingelheim GmbH
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Dr Kade Pharmazeutische Fabrik GmbH
- Fresenius Medical Care
- Fresenius SE & Co. KGaA
- GPC Biotech AG
- Graf von Westphalen
- Grünenthal GmbH
- Grünenthal Pharma GmbH & Co KG
- Grünenthal Pharma GmbH & Co. KG
- Grünenthal Pharma GmbH & Co.KG
- Intendis GmbH
- Jerini AG
- Morphosys AG
- Mundipharma GmbH
- Teva
- Umicore AG & Co. KG
- Vetter Pharma-Fertigung GmbH & Co KG
- Wilex AG
Denmark
- ALK-Abelló AS
- Ascendis Pharma A/S
- Chr. Hansen Holding A/S
- Dako Denmark AS
- Ferring Pharmaceuticals A/S
- Fertin Pharma
- Fertin Pharma A/S
- Fertin Pharma AS
- Genmab A/S
- Genmab AS
- Holst, Law Firm
- LEO Pharma
- Leo Pharma A S
- LEO Pharma A/S
- Leo Pharma AS
- Novo Nordisk A/S
- NsGene AS
- Roche Innovation Center Copenhagen
- Statens Serum Institut
- Tech Trans Unit
- Thrombologic ApS
- Veloxis Pharmaceuticals AS
- Xellia Pharmaceuticals
- Xellia Pharmaceuticals ApS
France
- Alexion R&D France
- Aptar
- Aptargroup UK Holdings Limited
- CEPI (Coalition for Epidemic Preparedness Innovations)
- ERYtech Pharma
- Flamel Technologies
- Laboratoires Bouchara Recordati
- LFB
- LFB BIOMEDICAMENTS
- MEDINCELL
- Mylan
- Mylan S.A.S.
- Mylan SAS
- none
- Nordic Pharma SAS
- Orphalan
- RECIPHARM
- Sanofi Aventis Group
- Sanofi Aventis Groupe
- Sanofi Aventis Recherche et Developpement
- Sanofi-Aventis
- Sanofi-Aventis Groupe
- Takeda
- TRANSGENE
Spain
- Accord Healthcare SLU
- Almirall, SA
- Assesora estudio jurídico y tributario S.L.P
- AstraZeneca Farmaceutica Spain, ss
- Bioiberica SA
- Chemo España
- CHEMO ESPAÑA, S.L.
- CHEMO Group
- Cloverty
- Corporación Medichem, SL
- INSUD PHARMA
- Isdin
- J Uriach y Compania SA
- Laboratories Hipra, S.A
- Laboratorios Almirall SA
- Laboratorios Liconsa, SA
- LACER SA
- Mabxience Holding
- Medichem
- MEDICHEM S,A,
- Moehs Iberica, Sl
Netherlands
- Astellas Pharma Europe B.V.
- AMT BV
- Crucell Holland BV
- DSM Sinochem Pharmaceuticals Netherlands B.V
- European Hematology Association
- Friesland Consumer Products
- Genzyme
- Intravacc
- Kite Pharma
- Mimetas B.V.
- PharmaMatch BV
- Pharming Group NV
- Sandoz
- Sanquin
- Sun Pharma
- Sun Pharmaceutical Industries (Europe) B.V.
- Sun Pharmaceutical Industries Europe BV
- Synthon BV
- University Medical Center Utrecht
- Xendo Holding B.V. – A ProPharma Group Company
Belgium
- Ablynx
- Ajino Moto - Omnichem
- Ajinomoto Omnichem\_Omnichem Division
- Aseptic Technologies
- Celyad SA
- GlaxoSmithKline
- GlaxoSmithKline Biologicals SA
- GSK
- GSK Biologicals SA
- Lonza Braine
- UCB Biopharma SPRL
- UCB Pharma
- UCB Pharma SA
- UCB S.A.
- UCB SA
- UCB SA/NV
- VIB
- VIB vzw
Italy
- Angelini Farmaceutica
- Aptuit (Verona) Srl
- CHIESI SPA
- Covidien Italia SpA
- Eli Lilly Italia Spa
- FIS FABBRICA ITALIANA SINTETICI S.P.A
- Fondazione Centro San Raffaele Del Monte Tabor
- GlaxoSmithKline
- GSK Vaccines SRL
- Molmed SpA
- Recordati S.p.A
- Roche SpA
- Sterling S.p.A.
- Studio Legale Lupi & Associati
Austria
- AOP Orphan Pharma
- Boehringer Ingelheim RCV GmbH & Co KG
- Boehringer Ingelheim RCV GmbH&Co KG
- Boehringer Ingelheim RCVGmbH & Co KG
- Boehringer-Ingelheim RCV GmbH & Co KG
- Ebewe Pharma
- Eli Lilly Regional Operations
- Hookipa Biotech GmbH
- Intercell AG
- Pharmaselect international Beteiligungs GmbH.
- Treibacher Industrie AG
Ireland
- Abbott Ireland Ltd
- Amarin
- BioMarin Pharmaceutical
- Elan Pharma International Ltd
- GH Research Ireland Ltd
- Horizon Therapeutics plc
- Jazz Pharma
- Jazz Pharmaceuticals
- Pfizer Ireland Pharmaceuticals
- Suir Pharma Ireland
Greece
- ELPEN Pharmaceutical Co. Inc.
- ELPEN S.A.
- Genesis Pharma SA
- Pharmathen
- Pharmathen SA
- PharOS - Pharmaceutical Oriented Services
- Scorinis Law Offices
Portugal
- ANGELINI FARMACEUTICA LDA
- BIAL
- BIAL - PORTELA & CA, S.A.
- BIAL - Portela & Companhia SA
- Bluepharma Industria Farmaceutica SA
United States of America
- Abbott Laboratories
- Emergent BioSolutions
- Grunenthal Latin America Inc.
- Savara Inc.
- SMC Ltd
Czech Republic
- AstraZeneca Czech Republic sro
- European PharmInvent Services, s.r.o.
- Institute of Chemical Technology Prague
- SOTIO a.s.
Russia
- Abbott Products
- GEROPHARM LLC
- Ispen Pharma
- Novartis Pharma LLC
Sweden
- AstraZeneca
- Astrazeneca Rod Ab
- PCG Clinical Services
- Recipharm AB (publ)
Norway
- Pharmaq AS
- Pronova Biopharma AS
- Pronova BioPharma Norge AS
Poland
- Kancelaria Radcy Prawnego
- Polpharma Trade Office
- Zaklady Farmaceutyczne Polpharma SA
Ukraine
- Acino Ukraine LLC, a company of Acino Group, Switzerland
- Arterium Corporation
- Farmak Joint Stock Company
Croatia
- JADRAN-GALENSKI LABORATORIJ d.d.
- Xellia d.o.o (Xellia Ltd)
Finland
- Orion Corporation
- Orion Corporation Orion Pharma
Korea, Republic Of
- Celltrion Inc.
- Samsung Bioepis
Latvia
- JSC Grindeks
- Julija Kolomijceva
Romania
- Roche Romania SRL
- TEVA Pharmaceuticals
Serbia
- Hemofarm AD
- Quintiles doo Beograd
Turkey
- K2 Events
- MN Pharmaceuticals
Australia
- Patrys Limited
Brazil
- NOVO NORDISK FARMACÊUTICA DO BRASIL LTD
Bulgaria
- Actavis EAD
Canada
- Transition Therapeutics
Colombia
- GrÜnenthal Colombiana
Cyprus
- Medochemie Ltd
Hungary
- Egis Pharmaceuticals PLC.
Jordan
- Hikma Pharmaceuticals
Luxembourg
- Menarini Int. Operations Luxembourg SA
Malaysia
- PHARMANIAGA BERHAD
Malta
- Starpharma Malta
Morocco
- Novartis Pharma Maroc SA
Qatar
- EBN Sina Medical Establishment
Saudi Arabia
- LFSH
Slovenia
- LEK Pharmaceuticals dd
United Arab Emirates
- Gulf Pharmaceutical Industries (Julphar)
Run Drafting Commercial Contracts for the Pharmaceutical Industry Live online for your team
2 days
Typical duration
Pricing from:
- GBP 800
- Per attendee, based on 10 attendees
- Course tailored to your requirements
- At your choice of location, or online
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
